interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Rizatriptan Benzoate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Rizatriptan Benzoate, and who makes it?

Rizatriptan Benzoate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 14.5 and 14.5 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Rizatriptan Benzoate3 dosage-form groups in the Orange Book
7generic makers listed
  1. Rizatriptan Benzoate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 7 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 14.5 and 14.5 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Maxalt. 6 generic makers with 12 generic products listed as marketed; the first generic approval is dated 31 December 2012.

1995200020052010201520202025203006brand 1998Aurobindo Pharma Ltd, first approval 31 December 2012Pharmazone, first approval 31 December 2012Teva Pharmaceuticals Usa, first approval 31 December 2012Chartwell Rx Sciences Llc, first approval 26 March 2013Macleods Pharmaceuticals Ltd, first approval 11 February 2014Alkem Laboratories Ltd, first approval 18 February 2016data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Aurobindo Pharma Ltd31 December 20122
Pharmazone31 December 20122
Teva Pharmaceuticals Usa31 December 20122
Chartwell Rx Sciences Llc26 March 20132
Macleods Pharmaceuticals Ltd11 February 20142
Alkem Laboratories Ltd18 February 20162

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Orally Disintegrating, Oral

One to three generic makers listed

Brand listed as marketed: Maxalt-Mlt. 3 generic makers with 6 generic products listed as marketed; the first generic approval is dated 31 December 2012.

1995200020052010201520202025203003brand 1998Aurobindo Pharma Ltd, first approval 1 July 2013Macleods Pharmaceuticals Ltd, first approval 19 September 2014Panacea Biotec Pharma Ltd, first approval 11 January 2017data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Aurobindo Pharma Ltd1 July 20132
Macleods Pharmaceuticals Ltd19 September 20142
Panacea Biotec Pharma Ltd11 January 20172

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Film, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Rizafilm. No generic is listed as marketed.

202020252030203501brand 2023data datePatent 9301948 listed to expire 30 July 2034
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 July 2034Patent 9301948 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.